bearish
China Healthcare Weekly (Mar.11) - 2022 Government Work Report, Expensive Monkeys, Technology Patent
194 Views13 Mar 2022 09:03
We listed the key points about healthcare industry in 2022 government work report. Companies should notice the skyrocketed experimental monkey price. Patents are not as decisive as might be expected.
SUMMARY
(Sign Up to Access)Get started on the Smartkarma Research Network with a complimentary Preview Pass to:
- Unlock all research summaries
- Follow top, independent analysts
- Receive personalised alerts and emails
- Access Briefings, Analytics, and Events
Upgrade anytime to our paid plans for full-length research, real-time analyst discussions, and more.
Join a thriving community of 45,000+ investors, including the top global asset managers managing over $13trn in assets.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 4-minute read)
Discussions
(Paid Plans Only)
Top 5%
Xinyao (Criss) Wang
HK/China Healthcare Analyst (ex-Fosun Pharma)
- Industry Report – Insights on China Surgical Robots Industry22 Mar 2022
- China Healthcare Weekly (Mar18)-Leaked Document On Medical Service,Biotech Valuation,CE Mark Upgrade20 Mar 2022
- The Impact of HFCAA on China ADR (China Healthcare Companies)16 Mar 2022
- China Healthcare Weekly (Mar.11) - 2022 Government Work Report, Expensive Monkeys, Technology Patent13 Mar 2022
- Russia-Ukraine War: The Impact on China Healthcare09 Mar 2022
- BeiGene Ltd (6160.HK/688235.CH) - There Is No Way to Retreat08 Mar 2022
- China Healthcare Weekly (Feb.25)-Assisted Reproduction, Medical Device Co. Globalization, New Growth27 Feb 2022
x